샘플 요청 목록

 카트 문의
시장보고서
상품코드
1514250

만성폐쇄성폐질환(COPD) 치료 시장

Chronic Obstructive Pulmonary Disease (COPD) Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 299 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 만성폐쇄성폐질환(COPD) 치료 시장은 2030년까지 278억 달러에 달할 전망

2023년에 204억 달러로 평가된 세계의 만성폐쇄성폐질환(COPD) 치료 시장은 분석 기간 2023년부터 2030년까지 CAGR 4.5%로 성장할 전망이며, 2030년에는 278억 달러에 달할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 배합제는 CAGR 4.9%로 성장을 지속하고, 분석 기간 종료 시 159억 달러에 달할 것으로 예측됩니다. 기관지 확장제 부문의 성장률은 분석 기간 동안 CAGR 4.3%로 추정됩니다.

미국 시장은 55억 달러로 추정, 중국은 CAGR 7.6%로 성장 예측

미국의 만성폐쇄성폐질환(COPD) 치료 시장은 2023년 55억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 59억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023년부터 2030년까지 CAGR은 7.6%로 전망됩니다. 다른 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.3%와 3.7%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 3.0%로 성장할 것으로 예측됩니다.

만성폐쇄성폐질환(COPD) 치료-주요 동향 및 촉진요인

만성폐쇄성폐질환(COPD)은 기류 폐색을 특징으로 하는 진행성 쇠약성 호흡기 질환으로 환자의 호흡을 어렵게 합니다. 만성 폐색성 폐 질환은 기도의 장기 염증을 수반하는 만성 기관지염과 폐의 기낭이 손상되는 폐기종이라는 두 가지 주요 질병을 포함합니다. COPD의 주요 원인은 유해한 자극물(가장 일반적인 담배 연기이지만 환경 오염 물질, 직업 먼지 및 화학 물질 등)에 장기간 노출되는 것입니다. 증상으로는 만성 기침, 점액 분비, 호흡 곤란, 빈번한 호흡기 감염 등이 있습니다. COPD는 환자의 QOL에 큰 영향을 미치며 호흡 부전과 같은 심각한 합병증을 유발할 수 있습니다. 조기 진단과 효과적인 관리는 질병 진행을 늦추고 환자의 예후를 개선하는 데 매우 중요합니다.

COPD의 치료는 증상의 개선, 폐 기능의 증진, 악화의 예방에 중점을 두고 해마다 크게 진보하고 있습니다. 약리학적 치료는 COPD 관리의 핵심이며 기관지 확장제, 코르티코스테로이드, 흡입제의 병용 등이 있습니다. 이 약은 기도 주위 근육을 이완시키고 염증을 억제하며 기류를 개선하는 데 도움이 됩니다. 이 외에도, 포스포디에스테라아제-4 억제제 및 단클론항체와 같은 새로운 치료제는 COPD의 병태에 관여하는 특정 경로를 표적화할 가능성이 고려되고 있습니다. 폐 재활, 산소 요법, 생활 습관 개선과 같은 비 약물 치료도 종합적인 COPD 관리 계획의 중요한 요소입니다. 운동 훈련, 영양 조언, 교육을 결합한 폐 재활 프로그램은 환자의 신체적, 정신적 건강 증진에 큰 효과를 보여줍니다.

COPD 치료 시장의 성장은 여러 요인에 의해 야기됩니다. 의료 기술, 특히 흡입기 설계 및 약물 전달 시스템의 진보는 치료의 효능과 편의성을 높이고 보급을 촉진합니다. COPD의 유병률 증가는 인구 고령화와 위험 요인에 대한 지속적인 노출을 유발하여 대응 가능한 환자 집단이 확대되고 있습니다. 또한 COPD에 대한 인식 증가와 조기 진단으로 더 많은 환자가 적시에 효과적인 치료를 받고 있습니다. 제약회사는 신규 치료법의 발견과 기존 치료법의 개선을 위해 연구개발에 많은 투자를 하고 있어 시장에 새로운 기회를 창출하고 있습니다. 또한 개별 환자 프로파일에 맞게 치료를 실시하는 맞춤형 의료로의 전환도 치료 성과를 최적화함으로써 성장에 박차를 가하고 있습니다. 또한 원격 의료 및 원격 모니터링 기술의 상승으로 COPD 관리가 용이해지고 적시 개입과 지속적인 치료가 가능합니다. 이러한 요인은 종합적으로 COPD 치료 시장의 성장을 뒷받침하고 세계 환자들에게 더 나은 관리와 삶의 질 향상을 보장합니다.

조사 대상 기업 예(총 53건)

  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici SpA
  • GlaxoSmithKline PLC
  • Mylan NV
  • Novartis International AG
  • Orion Corporation
  • Sunovion Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

AJY 24.07.24

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market to Reach US$27.8 Billion by 2030

The global market for Chronic Obstructive Pulmonary Disease (COPD) Treatment estimated at US$20.4 Billion in the year 2023, is expected to reach US$27.8 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2023-2030. Combination Drugs, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$15.9 Billion by the end of the analysis period. Growth in the Bronchodilators Drugs segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.5 Billion While China is Forecast to Grow at 7.6% CAGR

The Chronic Obstructive Pulmonary Disease (COPD) Treatment market in the U.S. is estimated at US$5.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.9 Billion by the year 2030 trailing a CAGR of 7.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Chronic Obstructive Pulmonary Disease (COPD) Treatment  - Key Trends and Drivers

Chronic Obstructive Pulmonary Disease (COPD) is a progressive and debilitating respiratory condition characterized by airflow obstruction, making it difficult for patients to breathe. The disease encompasses two main conditions: chronic bronchitis, which involves long-term inflammation of the airways, and emphysema, where the air sacs in the lungs are damaged. COPD is primarily caused by long-term exposure to harmful irritants, most commonly cigarette smoke, but also environmental pollutants and occupational dust and chemicals. Symptoms include chronic cough, mucus production, shortness of breath, and frequent respiratory infections. COPD significantly impacts patients' quality of life and can lead to severe complications, including respiratory failure. Early diagnosis and effective management are crucial in slowing disease progression and improving patient outcomes.

The treatment landscape for COPD has evolved significantly over the years, with a focus on improving symptoms, enhancing lung function, and preventing exacerbations. Pharmacological treatments are the cornerstone of COPD management and include bronchodilators, corticosteroids, and combination inhalers. These medications help to relax the muscles around the airways, reduce inflammation, and improve airflow. In addition to these, newer therapies such as phosphodiesterase-4 inhibitors and monoclonal antibodies are being explored for their potential to target specific pathways involved in COPD pathology. Non-pharmacological treatments, such as pulmonary rehabilitation, oxygen therapy, and lifestyle modifications, are also critical components of a comprehensive COPD management plan. Pulmonary rehabilitation programs, which combine exercise training, nutritional advice, and education, have shown significant benefits in enhancing patients' physical and emotional well-being.

The growth in the COPD treatment market is driven by several factors. Advances in medical technology, particularly in inhaler design and drug delivery systems, are enhancing the efficacy and convenience of treatments, thereby driving adoption. The increasing prevalence of COPD, partly due to aging populations and continued exposure to risk factors, is expanding the addressable patient population. Furthermore, heightened awareness and early diagnosis of COPD are resulting in more patients receiving timely and effective treatments. Pharmaceutical companies are investing heavily in research and development to discover novel therapies and improve existing treatments, generating new opportunities in the market. The shift towards personalized medicine, where treatments are tailored to individual patient profiles, is also spurring growth by optimizing therapeutic outcomes. Additionally, the rise in telemedicine and remote monitoring technologies is facilitating better management of COPD, allowing for timely interventions and continuous care. These factors collectively are propelling the growth of the COPD treatment market, ensuring better management and improved quality of life for patients worldwide.

Select Competitors (Total 53 Featured) -

  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici SpA
  • GlaxoSmithKline PLC
  • Mylan NV
  • Novartis International AG
  • Orion Corporation
  • Sunovion Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Inhaler Technology Propel Growth in COPD Treatment Market
    • Increasing Prevalence of COPD Expands Addressable Market Opportunity
    • Aging Population Spurs Demand for COPD Treatments
    • Enhanced Drug Delivery Systems Drive Adoption of COPD Therapies
    • Rise in Telemedicine and Remote Monitoring Generates New Market Opportunities
    • Early Diagnosis of COPD Accelerates Demand for Effective Treatments
    • Pharmaceutical Innovations in Bronchodilators and Corticosteroids Propel Market Growth
    • Integration of AI and Machine Learning in COPD Management Expands Market Reach
    • Development of Combination Therapies Generates Increased Market Demand
    • Adoption of Pulmonary Rehabilitation Programs Spurs Growth in COPD Treatment Market
    • Technological Innovations in Monoclonal Antibodies Create New Opportunities
    • Improved Diagnostic Tools Drive Early Detection and Treatment of COPD
    • Expansion of Healthcare Infrastructure in Emerging Markets Expands Addressable Market
    • Focus on Non-Pharmacological Treatments Enhances Comprehensive COPD Management
    • Growth in Home Healthcare Solutions Strengthens Business Case for COPD Treatments
    • Consumer Preference for Less Invasive Treatments Drives Demand for New COPD Therapies
    • Advancements in Genetic Research Propel Growth in Personalized COPD Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Phosphodiesterase Type 4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Phosphodiesterase Type 4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Phosphodiesterase Type 4 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Mucokinetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Mucokinetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Mucokinetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: China 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: France 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Germany 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Italy 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: UK 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 53: Spain Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Spain Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Spain 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Russia Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Russia 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 59: Rest of Europe Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Rest of Europe Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Rest of Europe 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Asia-Pacific 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 68: Australia Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Australia Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Australia 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • INDIA
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 71: India Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: India Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: India 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 74: South Korea Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: South Korea Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: South Korea 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 77: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Rest of Asia-Pacific Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Rest of Asia-Pacific 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Latin America 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 86: Argentina Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Argentina Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Argentina 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 89: Brazil Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Brazil Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Brazil 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 92: Mexico Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Mexico Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Mexico 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 95: Rest of Latin America Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Latin America Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Latin America 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Middle East 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 104: Iran Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Iran Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Iran 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 107: Israel Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Israel Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Israel 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 110: Saudi Arabia Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Saudi Arabia Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Saudi Arabia 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 113: UAE Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UAE Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UAE 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 116: Rest of Middle East Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Middle East Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Middle East 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • AFRICA
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 119: Africa Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Africa Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Africa 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제